Table 3. Multivariate analysis of the influence of the guideline publication.
| Parameters | HR | 95% CI | p-value | |
|---|---|---|---|---|
| 2004–2006 | 1.000 (reference) | - | - | |
| 2007–2009 | 0.891 | 0.759–1.046 | 0.160 | |
| Year | 1.020 | 0.972–1.069 | 0.423 | |
| Age | 1.002 | 1.001–1.002 | <0.001 | |
| Stage | ||||
| I | 1.000 (reference) | - | - | |
| II | 2.281 | 1.913–2.718 | <0.001 | |
| III | 5.695 | 5.079–6.387 | <0.001 | |
| IV | 14.017 | 12.287–15.990 | <0.001 | |
| Histology | ||||
| Endometrioid grade 1 | 1.000 (reference) | - | - | |
| Endometrioid grade 2 | 2.481 | 2.166–2.842 | <0.001 | |
| Endometrioid grade 3 | 4.149 | 3.594–4.790 | <0.001 | |
| Endometrioid grade unknown | 3.372 | 2.595–4.381 | <0.001 | |
| Serous/clear-cell | 5.424 | 4.690–6.272 | <0.001 | |
| Others | 6.712 | 5.833–7.723 | <0.001 | |
| Primary treatment | ||||
| Surgery with LA | 1.000 (reference) | - | - | |
| Surgery without LA | 1.992 | 1.810–2.192 | <0.001 | |
| Radiation therapy* | 4.969 | 3.842–6.427 | <0.001 | |
| Chemotherapy | 2.508 | 2.198–2.862 | <0.001 | |
| Others | 4.828 | 3.228–7.221 | <0.001 | |
CI, confidence interval; EBRT, extra-beam radiation therapy; HR, hazard ratio; ICBT, intracavitary brachytherapy; LA, lymphadenectomy.
*Including both EBRT and ICBT.